Prestige Biologics (Korea) Performance
334970 Stock | KRW 5,330 360.00 6.33% |
The company holds a Beta of -0.1, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Prestige Biologics are expected to decrease at a much lower rate. During the bear market, Prestige Biologics is likely to outperform the market. At this point, Prestige Biologics has a negative expected return of -0.0902%. Please make sure to check Prestige Biologics' market risk adjusted performance, coefficient of variation, jensen alpha, as well as the relationship between the mean deviation and standard deviation , to decide if Prestige Biologics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Prestige Biologics Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Prestige Biologics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Total Cashflows From Investing Activities | -97.9 B |
Prestige |
Prestige Biologics Relative Risk vs. Return Landscape
If you would invest 585,000 in Prestige Biologics Co on September 1, 2024 and sell it today you would lose (52,000) from holding Prestige Biologics Co or give up 8.89% of portfolio value over 90 days. Prestige Biologics Co is generating negative expected returns and assumes 3.6629% volatility on return distribution over the 90 days horizon. Simply put, 32% of stocks are less volatile than Prestige, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
Risk |
Prestige Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prestige Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Prestige Biologics Co, and traders can use it to determine the average amount a Prestige Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0246
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | 334970 |
Estimated Market Risk
3.66 actual daily | 32 68% of assets are more volatile |
Expected Return
-0.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Prestige Biologics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Prestige Biologics by adding Prestige Biologics to a well-diversified portfolio.
Prestige Biologics Fundamentals Growth
Prestige Stock prices reflect investors' perceptions of the future prospects and financial health of Prestige Biologics, and Prestige Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Prestige Stock performance.
Return On Equity | -53.64 | |||
Current Valuation | 555.64 B | |||
Revenue | 3.23 B | |||
EBITDA | (12.84 B) | |||
Cash And Equivalents | 36.77 B | |||
Total Debt | 71.54 B | |||
Cash Flow From Operations | (25.87 B) | |||
Total Asset | 206.77 B | |||
About Prestige Biologics Performance
By analyzing Prestige Biologics' fundamental ratios, stakeholders can gain valuable insights into Prestige Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Prestige Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Prestige Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. The company was founded in 2015 and is based in Cheongju-si, South Korea. Prestige Biologics is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about Prestige Biologics performance evaluation
Checking the ongoing alerts about Prestige Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Prestige Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Prestige Biologics generated a negative expected return over the last 90 days | |
Prestige Biologics has high historical volatility and very poor performance | |
The company reported the revenue of 3.23 B. Net Loss for the year was (39.38 B) with loss before overhead, payroll, taxes, and interest of (2.88 M). | |
Prestige Biologics Co has accumulated about 36.77 B in cash with (25.87 B) of positive cash flow from operations. |
- Analyzing Prestige Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Prestige Biologics' stock is overvalued or undervalued compared to its peers.
- Examining Prestige Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Prestige Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Prestige Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Prestige Biologics' stock. These opinions can provide insight into Prestige Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Prestige Stock analysis
When running Prestige Biologics' price analysis, check to measure Prestige Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prestige Biologics is operating at the current time. Most of Prestige Biologics' value examination focuses on studying past and present price action to predict the probability of Prestige Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prestige Biologics' price. Additionally, you may evaluate how the addition of Prestige Biologics to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Stocks Directory Find actively traded stocks across global markets | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Content Syndication Quickly integrate customizable finance content to your own investment portal |